Summary
- Main use
- Nutritional improvement through omega-3 (DHA·EPA) supplementation in patients receiving parenteral nutrition
- Who uses it
- Adults
- Adult dosage
- Daily dose: Up to 1 mL to 2 mL/kg body weight of Omegaven = 0.1 g to 0.2 g/kg body weight as purified fish oil = For a patient weighing 70 kg, administer 70 – 140 mL of Omegaven. Omegaven should be administered together with other fat emulsions. In this case, Omegaven should account for 10 - 20% of the total fat intake, and the total fat dose should not exceed 2 g/kg body weight/day. Maximum infusion rate: 0.5 mL/kg body weight/hour of Omegaven = 0.05 g/kg body weight/hour as purified fish oil The maximum infusion rate must not be exceeded, as doing so may cause a rapid increase in serum triglyceride levels. Route of administration: Administer by intravenous infusion through a central or peripheral vein. Shake well before use. If administered through the same line (by-pass, Y-stick) with other injectable solutions (e.g., amino acid solutions, carbohydrate solutions), compatibility with each solution must be ensured. Duration of administration: The duration of administration should not exceed 4 weeks.
Ingredients
- Importer
- Fresenius Kabi Korea Ltd.
Efficacy & effects
Nutritional improvement through omega-3 (DHA·EPA) supplementation in patients receiving parenteral nutrition
View approved original textHide original text
Omega-3 fatty acids, especially DHA and EPA, help improve nutrition in patients who require parenteral nutrition and for whom oral or enteral nutrition is difficult or insufficient.
Dosage and Administration
Adult dosage
Daily dose: Up to 1 mL to 2 mL/kg body weight of Omegaven = 0.1 g to 0.2 g/kg body weight as purified fish oil = For a patient weighing 70 kg, administer 70 – 140 mL of Omegaven. Omegaven should be administered together with other fat emulsions. In this case, Omegaven should account for 10 - 20% of the total fat intake, and the total fat dose should not exceed 2 g/kg body weight/day. Maximum infusion rate: 0.5 mL/kg body weight/hour of Omegaven = 0.05 g/kg body weight/hour as purified fish oil The maximum infusion rate must not be exceeded, as doing so may cause a rapid increase in serum triglyceride levels. Route of administration: Administer by intravenous infusion through a central or peripheral vein. Shake well before use. If administered through the same line (by-pass, Y-stick) with other injectable solutions (e.g., amino acid solutions, carbohydrate solutions), compatibility with each solution must be ensured. Duration of administration: The duration of administration should not exceed 4 weeks.
Precautions
This medication must only be used under a physician's direction. If severe allergic reactions such as anaphylaxis occur, use must be discontinued immediately. It should not be used in patients with severe bleeding disorders or in life-threatening conditions such as acute myocardial infarction or stroke. It should not be administered to patients with abnormal fat metabolism or severe liver or kidney dysfunction. Due to a lack of experience in using this medication, it should not be given to premature infants, newborns, or children. Do not use this medication if allergic to fish or egg proteins. Cautious use is required in patients with dyslipidemia or uncontrolled diabetes, and those taking anticoagulants. Adverse reactions related to blood coagulation can occur rarely, requiring careful monitoring. During administration, levels of serum triglycerides, blood glucose, electrolytes, and blood counts should be regularly tested. When administering fat emulsions, serum triglyceride levels should be managed to not exceed a certain level, and if adverse reactions appear, the dosage should be adjusted or discontinued. During pregnancy or breastfeeding, it should only be used cautiously when absolutely necessary. In cases of overdose, side effects like fat overload syndrome or metabolic acidosis may occur; therefore, the rate and amount of administration must be strictly controlled. Before use, shake the container well to ensure it is homogeneous, and do not use damaged containers. It is advisable to use infusion equipment that does not contain phthalates, and compatibility should be checked when mixing with other infusions. Care should be taken not to exceed the maximum administration rate, and the duration of administration should not exceed four weeks. Unused medication must be discarded, and storage should be at temperatures below 25 degrees Celsius without freezing.
Side effects
Prolonged bleeding time, platelet aggregation disorder, metallic taste, thrombocytopenia, hemolysis, reticulocytosis, abdominal pain, nausea, vomiting, increased body temperature, chills, cold symptoms, fatigue, anaphylactic reaction, transient elevation of liver function tests, hypertriglyceridemia, headache, priapism, skin rash, urticaria, circulatory abnormalities, symptoms of thrombocytopenia, splenomegaly, changes in blood coagulation parameters, splenomegaly, anemia, leukopenia, bleeding, abnormal liver function tests, fever, hyperlipidemia, hyperglycemia
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a sealed container to prevent exposure to air or moisture. The storage temperature should be maintained at or below 25 degrees Celsius, taking care not to freeze.
Appearance and packaging
Appearance
A vial containing a white, homogeneous emulsion.
Package unit
50mL/vial x 10, 100mL/vial x 10
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.